Johnson & Johnson (NYSE:JNJ) has received FDA approval to expand the current labeling ... Accordingly, the treatment-targeting B-cell maturation antigen (BCMA) will be indicated in the U.S ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies ... and Pfizer’s Elrexfio (elranatamab), which are already FDA-approved in this indication, and the jury is out ...

The new double-headed antibody targets both CD3 and BCMA, a target that already features in approved therapies for ... autoleucel – now heading for an FDA verdict by 28 February after a three ...

These numbers are comparable to the results of the phase II CARTITUDE-1 trial that led to cilta-cel's approval by the ... B cell maturation antigen (BCMA), a protein found on multiple myeloma ...

The FDA has approved five medicines that target BCMA for myeloma as of January 2024. An antibody-drug conjugate (ADC) targeting CD30, Brentuximab vedotin, has also been approved by the FDA to ...

Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy that first won FDA approval in 2021 as the first FDA-approved chimeric antigen receptor T ...

CAMBRIDGE, Mass., March 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights ...

They co-developed Abecma (idecabtagene vicleucel), a BCMA-targeted chimeric antigen ... which secured US Food and Drug Administration (FDA) approval in April 2024. However, Abecma has faced ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...